These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 9508381)

  • 1. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
    Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
    Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
    Mihm MC; Clemente CG; Cascinelli N
    Lab Invest; 1996 Jan; 74(1):43-7. PubMed ID: 8569196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis after sentinel node biopsy in malignant melanoma].
    Lock-Andersen J; Horn J; Sjøstrand H
    Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vulvar melanoma: is there a role for sentinel lymph node biopsy?
    de Hullu JA; Hollema H; Hoekstra HJ; Piers DA; Mourits MJ; Aalders JG; van der Zee AG
    Cancer; 2002 Jan; 94(2):486-91. PubMed ID: 11905414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
    Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
    Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical technique and postoperative morbidity following radical inguinal/iliacal lymph node dissection--a prospective study in 67 patients with malignant melanoma metastatic to the groin].
    Mall JW; Reetz C; Koplin G; Schäfer-Hesterberg G; Voit C; Neuss H
    Zentralbl Chir; 2009 Sep; 134(5):437-42. PubMed ID: 19757344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined-modality therapy for patients with regional nodal metastases from melanoma.
    Ballo MT; Ross MI; Cormier JN; Myers JN; Lee JE; Gershenwald JE; Hwu P; Zagars GK
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):106-13. PubMed ID: 16182463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
    Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
    J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin.
    Allan CP; Hayes AJ; Thomas JM
    ANZ J Surg; 2008 Nov; 78(11):982-6. PubMed ID: 18959697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.